Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy
Gastrointestinal stromal tumors (GISTs) are rare malignancies, and historically had a poor prognosis, with little benefit from traditional anticancer therapies. The management of GISTs has undergone a paradigm change in recent years with the detection of activating mutations in the majority of these...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publishing
2014-09-01
|
| Cyfres: | Therapeutic Advances in Medical Oncology |
| Mynediad Ar-lein: | https://doi.org/10.1177/1758834014544892 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|